| 联合检测CYFRA21-1和NSE对肺癌胸腔积液的诊断价值 |
| |
| 引用本文： | 陈飞鹏,邬勇坚.联合检测CYFRA21-1和NSE对肺癌胸腔积液的诊断价值[J].中华生物医学工程杂志,2001,7(2). |
| |
| 作者姓名： | 陈飞鹏 邬勇坚 |
| |
| 作者单位： | 广州医学院第二附属医院呼吸科 |
| |
| 摘 要： | 目的探讨联合检测肿瘤标记物水溶性细胞角质蛋白19片段（CYFRA21-1）、神经原特异性烯醇化酶（NSE）对肺癌胸腔积液的诊断价值.方法用放射免疫法测定非小细胞肺癌（NSCLC）32 例、小细胞肺癌（SCLC）11例及良性胸腔积液30例患者的胸液中CYFRA21-1和NSE水平.结果胸液CYFRA21-1水平和NSE水平在不同类型肺癌胸腔积液均有不同程度升高.CYFRA21-1在NSCLC胸液的阳性率为78.1%，在SCLC胸液的阳性率为36.4%，而NSE在NSCLC胸液的阳性率为46.9%，在SCLC胸液的阳性率为72.7%.联合检查能提高对肺癌胸腔积液诊断的敏感性和特异性.结论检测胸液CYFRA21-1和NSE对肺癌胸腔积液有一定的诊断价值，联合检测综合判断更能提高诊断准确率.
|
| 关 键 词： | 肺癌 胸腔积液 神经原特异性烯醇化酶 细胞角质蛋白19片段 |
The Value of Assay of CYFRA21-1 Combined with NSE in Pleural Fluid for the Diagnosis of Lung Cancer |
| |
| CHEN Fei-peng,WU Yong-jian.The Value of Assay of CYFRA21-1 Combined with NSE in Pleural Fluid for the Diagnosis of Lung Cancer[J].Chinese Journal of Biomedical Engineering,2001,7(2). |
| |
| Authors: | CHEN Fei-peng WU Yong-jian |
| |
| Abstract: | Objective To investigate the value of testing CYFRA21-1 combined with NSE in pleural fluid for the diagnosis of lung cancer.Methods CYFRA21-1 and NSE were measured by RIA. Pleural fluid samples were determined from 32 patients with NSCLC, 11 patients with SCLC and 30 patients with benign diseases. Results The levels and positive rates of CYFRA21-1 and NSE in the pleural fluid of NSCLC and SCLC were significantly higher than that in benign pleural fluid (p＜0.05) Conclusions It is better that assay of CYFRA21-1 combined with NSE than that singly in the diagnosis of lung cancer with pleural fluid. |
| |
| Keywords: | |
| 本文献已被 万方数据 等数据库收录！ |
